Antiplatelet pyrazolopyridines derivatives: pharmacological, biochemical and toxicological characterization

References

• Versteeg HH, Heemskerk JWM, Levi M, Reitsma PH. New fundamentals in hemostasis. Physiol Rev 2013;93:327–58
   PubMed Web of Science ®Google Scholar
• WHO. World Health Organization [Internet]; 2014. Available from: http://www.who.int/nmh/publications/ncd-status-report-2014/en/ [last accessed 10 Jan 2016]
   Google Scholar
• Angiolillo DJ, Datto C, Raines S, Yeomans ND. Impact of concomitant low-dose aspirin on the safety and tolerability of naproxen and esomeprazole magnesium delayed-release tablets in patients requiring chronic nonsteroidal anti-inflammatory drug therapy: an analysis from 5 Phase III studies. J Thromb Thrombolysis 2013;38:11–23
   Web of Science ®Google Scholar
• Shah R, Keough LA, Belalcazar-Portacio A, Ramanathan KB. Ticagrelor as an alternative in clopidogrel-associated neutropenia. Platelets 2014;16:1–3
   Google Scholar
• Kunadian V, Sinclair H, Sutton A, Dangas GD. Aspirin, platelet P2Y12 receptor inhibitors, and other oral antiplatelets: comparative pharmacology and role in elective PCI. Intervent Cardiol Clin 2013;2:527–35
   PubMedGoogle Scholar
• Choi J-T, Shin K-A, Kim Y-K, Prevalence of aspirin resistance and clinical characteristics in patients with cerebral infarction. Kor Soc Biomed Lab Sci 2013;30:233–8
   Google Scholar
• Galanaud J-P, Laroche J-P, Righini M. The history and historical treatments of deep vein thrombosis. J Thromb Haemost 2013;11:402–11
   PubMed Web of Science ®Google Scholar
• Geraldo RB, Bello ML, Dias LRS, et al. Antiplatelet activity and structure-activity relationship study of pyrazolopyridine derivatives as potential series for treating thrombotic diseases. J Atheroscler Thromb 2010;17:730–9
   PubMed Web of Science ®Google Scholar
• Pinheiro LCS, Abreu PA, Afonso IF, et al. Identification of a potential lead structure for designing new antimicrobials to treat infections caused by Staphylococcus epidermidis-resistant strains. Curr Microbiol 2008;57:463–8
   PubMed Web of Science ®Google Scholar
• Vera-Divaio MAF, Freitas ACC, Castro HC, et al. Synthesis, antichagasic in vitro evaluation, cytotoxicity assays, molecular modeling and SAR/QSAR studies of a 2-phenyl-3-(1-phenyl-1H-pyrazol-4-yl)-acrylic acid benzylidene-carbohydrazide series. Bioorg Med Chem 2009;17:295–302
   PubMed Web of Science ®Google Scholar
• Dias LRS, Alvim MJ, Freitas ACC, et al. Synthesis and analgesic properties of 5-acyl-arylhydrazone 1-H pyrazolo [3,4-b] pyridine derivatives. Pharm Acta Helv 1994;69:163–9
   PubMedGoogle Scholar
• Mostafa MG, Al-Said MS. Antitumor activity of novel pyridine, thiophene and thiazole derivatives. Arch Pharm Res 2012;35:965–73
   PubMed Web of Science ®Google Scholar
• Pinto DJP, Orwat MJ, Koch S, et al. Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4- c] pyridine-3-carboxamide (Apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa. J Med Chem 2007;50:5339–56
   PubMed Web of Science ®Google Scholar
• Dias LRS, Santos MB, Albuquerque Sd, et al. Synthesis, in vitro evaluation, and SAR studies of a potential antichagasic 1H-pyrazolo[3,4-b]pyridine series. Bioorg Med Chem 2007;15:211–19
   PubMed Web of Science ®Google Scholar
• COBEA. Princípios éticos na experimentação animal [Internet]; 1991 [cited 2013 Jan 1]. Available from: Disponível em <http://www.cobea.org.br> [last accessed 1 Jan 2013]
   Google Scholar
• CARE. Guidelines for Ethical Conduct in the Care and Use of Animals developed by APA’s [Internet]; 2012 [cited 2013 Jan 1]. Available from: http://www.apa.org/science/anguide.html
   Google Scholar
• Pierdoná TM, Lima NR, Rodrigues RCM, et al. The Operculina macrocarpa (l.) urb. (jalapa) tincture modulates human blood platelet aggregation. J Ethnopharmacol 2014;151:151–7
   PubMed Web of Science ®Google Scholar
• Sathler PC, Lourenço AL, Rodrigues CR, et al. In vitro and in vivo analysis of the antithrombotic and toxicological profile of new antiplatelets N-acylhydrazone derivatives and development of nanosystems: determination of novel NAH derivatives antiplatelet and nanotechnological approach. Thromb Res 2014;134:376–83
   PubMed Web of Science ®Google Scholar
• Bauer M, Lautenschlaeger C, Kempe K, et al. Poly(2-ethyl-2-oxazoline) as alternative for the stealth polymer poly(ethylene glycol): comparison of in vitro cytotoxicity and hemocompatibility. Macromol Biosci 2012;12:986–98
   PubMed Web of Science ®Google Scholar
• Faye E, Drouet L, De Raucourt E, et al. Absorption and efficacy of acetylsalicylic acid in patients with short bowel syndrome. Ann Pharmacother 2014;48:705–10
   PubMed Web of Science ®Google Scholar
• Leal B, Afonso IF, Rodrigues CR, et al. Antibacterial profile against drug-resistant Staphylococcus epidermidis clinical strain and structure–activity relationship studies of 1H-pyrazolo[3,4-b]pyridine and thieno[2,3-b]pyridine derivatives. Bioorg Med Chem 2008;16:8196–204
   PubMed Web of Science ®Google Scholar
• Cosconati S, Forli S, Perryman AL, et al. Virtual screening with AutoDock: theory and practice. Expert Opin Drug Discov 2010;5:597–607
   PubMed Web of Science ®Google Scholar
• Lourenço AL, Abreu PA, Leal B, et al. Identification of Nor-β-lapachone derivatives as potential antibacterial compounds against Enterococcus faecalis clinical strain. Curr Microbiol 2011;62:684–9
   PubMed Web of Science ®Google Scholar
• Santos CBR, Lobato CC, Braga FS, et al. Application of Hartree–Fock method for modeling of bioactive molecules using SAR and QSPR. Comput Mol Biosci 2014;4:1–24
   Google Scholar
• Sathler PC, Santana M, Lourenço AL, et al. Human thromboxane synthase: comparative modeling and docking evaluation with the competitive inhibitors dazoxiben and ozagrel. J Enzyme Inhib Med Chem 2014;29:527–31
   PubMed Web of Science ®Google Scholar
• Meng X-Y, Zhang H-X, Mezei M, Cui M. Molecular docking: a powerful approach for structure-based drug discovery. Curr Comput Aided Drug Des 2011;7:146–57
   PubMed Web of Science ®Google Scholar
• Magalhães WS, Corrêa CM, Alencastro RBd, Nagem TJ. Bases moleculares da ação anti-inflamatória dos ácidos oleanólico e ursólico sobre as isoformas da ciclo-oxigenase por docking e dinâmica molecular. Quim Nova 2012;35:241–8
   Web of Science ®Google Scholar
• Bullock CW, Jacob RB, McDougal OM, et al. Dockomatic – automated ligand creation and docking. BMC Res Notes 2010;3:289
   PubMedGoogle Scholar
• Treuting PM, Dintzis SM. Comparative anatomy and histology: a mouse and human atlas. 1st ed. Amsterdam, Boston: Academic Press; 2011. 474 p
   Google Scholar
• Liu Y, Jennings NL, Dart AM, Du X-J. Standardizing a simpler, more sensitive and accurate tail bleeding assay in mice. World J Exp Med 2012;2:30–6
   PubMedGoogle Scholar
• Wang X, Chen X, Xing L, et al. Blood compatibility of a new zwitterionic bare metal stent with hyperbranched polymer brushes. J Mater Chem B 2013;1:5036
   PubMed Web of Science ®Google Scholar
• Fischer D, Li Y, Ahlemeyer B, et al. In vitro cytotoxicity testing of polycations: influence of polymer structure on cell viability and hemolysis. Biomaterials 2003;24:1121–31
   PubMed Web of Science ®Google Scholar
• Bhattacharyya DK, Lecomte M, Rieke CJ. Involvement of arginine 120, glutamate 524, and tyrosine 355 in the binding of arachidonate and 2-phenylpropionic acid inhibitors to the cyclooxygenase active site of ovine prostaglandin endoperoxide H synthase-1. J Biol Chem 1996;271:2179–84
   PubMed Web of Science ®Google Scholar
• Harman CA, Turman MV, Kozak KR, et al. Structural basis of enantioselective inhibition of cyclooxygenase-1 by S-alpha-substituted indomethacin ethanolamides. J Biol Chem 2007;282:28096–105
   PubMed Web of Science ®Google Scholar
• Goltsov A, Lebedeva G, Humphery-Smith I, et al. In silico screening of nonsteroidal anti-inflammatory drugs and their combined action on prostaglandin H synthase-1. Pharmaceuticals (Basel) 2010;3:2059–81
   PubMedGoogle Scholar
• Nakahata N. Thromboxane A2: physiology/pathophysiology, cellular signal transduction and pharmacology. Pharmacol Ther 2008;118:18–35
   PubMed Web of Science ®Google Scholar
• Fintel D. Oral antiplatelet therapy for atherothrombotic disease: overview of current and emerging treatment options. Vasc Health Risk Manage 2012;8:77–89
   PubMedGoogle Scholar
• Zhang H, Holden-Wiltse J, Wang J, Liang H. A strategy to model nonmonotonic dose-response curve and estimate IC50. PLoS One 2013;8:e69301
   PubMed Web of Science ®Google Scholar
• Peters RJG, Mehta SR, Fox KAA, et al. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Study. Circulation 2003;108:1682–7
   PubMed Web of Science ®Google Scholar
• Zhong S-R, Jin Y, Wu J-B, et al. Characterization and molecular cloning of dabocetin, a potent antiplatelet C-type lectin-like protein from Daboia russellii siamensis venom. Toxicon 2006;47:104–12
   PubMed Web of Science ®Google Scholar
• Terashita Z, Imura Y, Kawamura M, et al. Effects of thromboxane A2 synthase inhibitors (CV-4151 and ozagrel), aspirin, and ticlopidine on the thrombosis caused by endothelial cell injury. Thromb Res 1995;77:411–21
   PubMed Web of Science ®Google Scholar
• Capra V, Bäck M, Angiolillo DJ, et al. Impact of vascular thromboxane prostanoid receptor activation on hemostasis, thrombosis, oxidative stress, and inflammation. J Thromb Haemost 2014;12:126–37
   PubMed Web of Science ®Google Scholar
• Strack AM, Carballo-Jane E, Wang S, et al. Nicotinic acid and DP1 blockade: studies in mouse models of atherosclerosis. J Lipid Res 2013;54:177–88
   PubMed Web of Science ®Google Scholar
• Needleman P, Truk J, Jakschik BA, et al. Arachidonic acid metabolism. Annu Rev Biochem 1986;55:69–102
   PubMed Web of Science ®Google Scholar
• Santiago E, Contreras C, García-Sacristán A, et al. Signaling pathways involved in the H2O2-induced vasoconstriction of rat coronary arteries. Free Radic Biol Med 2013;60:136–46
   PubMed Web of Science ®Google Scholar
• Sadilkova L, Paluch Z, Mottlova J, et al. The purification step is not crucial in EIA measurements of thromboxane B2 and 11-dehydrothromboxane B2 in human plasma. Clin Lab 2012;58:177–83
   PubMed Web of Science ®Google Scholar
• Cuendet M, Mesecar AD, DeWitt DL, Pezzuto JM. An ELISA method to measure inhibition of the COX enzymes. Nat Protoc 2006;1:1915–21
   PubMed Web of Science ®Google Scholar
• Uno K, Iuchi Y, Fujii J, et al. In vivo study on cross talk between inducible nitric-oxide synthase and cyclooxygenase in rat gastric mucosa: effect of cyclooxygenase activity on nitric oxide production. J Pharmacol Exp Ther 2004;309:995–1002
   PubMed Web of Science ®Google Scholar
• Fontana P, Zufferey A, Daali Y, Reny J-L. Antiplatelet therapy: targeting the TxA2 pathway. J Cardiovasc Transl Res 2013;7:29–38
   PubMed Web of Science ®Google Scholar
• Cathcart MC, Gately K, Cummins R, et al. Thromboxane synthase expression and correlation with VEGF and angiogenesis in non-small cell lung cancer. Biochim Biophys Acta (BBA) 2014;1842:747–55
   PubMed Web of Science ®Google Scholar
• Yanai TK, Mori S. Mechanistic insights into prostanoid transformations catalyzed by cytochrome P450. Prostacyclin and thromboxane biosyntheses. Adv Med Bio [Internet]; 2011 [cited 2013 Sep 18]. Available from: http://smori.sci.ibaraki.ac.jp/978-1-61122-467-2_ch8.pdf
   Google Scholar
• Chao W-C, Lu J-F, Wang J-S, et al. Probing ligand binding to thromboxane synthase. Biochemistry 2013;52:1113–21
   PubMed Web of Science ®Google Scholar
• Ortiz de Montellano PR, Kunze KL, Augusto O. Hemoprotein destruction. Iron-nitrogen shift of a phenyl group in a porphyrin complex. J Am Chem Soc 1982;104:3545–6
   Web of Science ®Google Scholar
• Montellano PRO, de Chan WK, et al. Mechanism-based probes of the topology and function of fatty acid hydroxylases. FASEB J 1992;6:695–9
   PubMed Web of Science ®Google Scholar
• Ruan K-H, Milfeld K, Kulmacz RJ, Wu KK. Comparison of the construction of a 3-D model for human thromboxane synthase using P450cam and BM-3 as templates: implications for the substrate binding pocket. Protein Eng 1994;7:1345–51
   PubMedGoogle Scholar
• Liedtke AJ, Crews BC, Daniel CM, et al. Cyclooxygenase-1-selective inhibitors based on the (E)-2′-des-methyl-sulindac sulfide scaffold. J Med Chem 2012;55:2287–300
   PubMed Web of Science ®Google Scholar
• Singh AK, Singh N, Sinha M, et al. Binding modes of aromatic ligands to mammalian heme peroxidases with associated functional implications. J Biol Chem 2009;284:20311–18
   PubMed Web of Science ®Google Scholar
• Meunier B, de Visser SP, Shaik S. Mechanism of oxidation reactions catalyzed by cytochrome P450 enzymes. Chem Rev 2004;104:3947–80
   PubMed Web of Science ®Google Scholar
• Saxena A, Balaramnavar VM, Hohlfeld T, Saxena AK. Drug/drug interaction of common NSAIDs with antiplatelet effect of aspirin in human platelets. Eur J Pharmacol 2013;721:215–24
   PubMed Web of Science ®Google Scholar
• Daham K, James A, Balgoma D, et al. Effects of selective COX-2 inhibition on allergen-induced bronchoconstriction and airway inflammation in asthma. J Allergy Clin Immunol [Internet]; 2014 [cited 2015 Jan 28]. Available from: http://www.sciencedirect.com/science/article/pii/S0091674913018538
   PubMed Web of Science ®Google Scholar
• Delcroix M, Melot C, Lejeune P, et al. Cyclooxygenase inhibition aggravates pulmonary hypertension and deteriorates gas exchange in canine pulmonary embolism. Am Rev Respir Dis 1992;145:806–10
   PubMed Web of Science ®Google Scholar
• Smulders YM. Pathophysiology and treatment of haemodynamic instability in acute pulmonary embolism: the pivotal role of pulmonary vasoconstriction. Cardiovasc Res 2000;48:23–33
   PubMed Web of Science ®Google Scholar
• Petri MH, Tellier C, Michiels C, et al. Effects of the dual TP receptor antagonist and thromboxane synthase inhibitor EV-077 on human endothelial and vascular smooth muscle cells. Biochem Biophys Res Commun 2013;441:393–8
   PubMed Web of Science ®Google Scholar
• Bassand J-P. Current antithrombotic agents for acute coronary syndromes: focus on bleeding risk. Int J Cardiol 2013;163:5–18
   PubMed Web of Science ®Google Scholar
• Patrono C. Role of clinical pharmacology in the development of antiplatelet drugs. Clin Therapeut 2014;36:2096–111
   PubMed Web of Science ®Google Scholar